NEW YORK, Jan. 27 /PRNewswire-FirstCall/ -- Gilda’s Club New York City last night presented its Award for the Advancement of Cancer Medicine to Patrick Soon-Shiong, M.D., FACS and Larry Norton, M.D. at its 11th Annual Black Tie Gala held at The Pierre Hotel, New York. The presentation was made by the Honorable Rudolph Giuliani, former New York City Mayor.
Dr. Soon-Shiong is the founder and chief executive officer of American BioScience, Inc. and American Pharmaceutical Partners, Inc. Dr. Norton is Deputy Physician-in-Chief, Memorial Hospital (For Breast Cancer Programs). The Gilda’s Club New York City Award for the Advancement of Cancer Medicine is provided to individuals who have made significant contributions to improving the lives of those living with cancer.
Dr. Soon-Shiong was honored for his work in developing the first nanoparticle chemotherapy technology, ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), launched in February 2005 for the treatment of metastatic breast cancer. This revolutionary technology is the first protein-bound chemotherapy to be approved and has shown to improve the outcomes in patients suffering from breast cancer. Dr. Norton was honored for his commitment to people with breast cancer through his work at Memorial Sloan Kettering Cancer Center and his leadership in developing a dose-dense regimen which has enhanced the outcome of chemotherapy in breast cancer.
Named for Saturday Night Live comedienne Gilda Radner, Gilda’s Club New York City opened in 1995 as a meeting place where men, women and children touched by any type of cancer, including their families and friends, can join with others to build emotional and social support as a supplement to medical care. Free of charge and nonprofit, Gilda’s Club New York City offers support and network groups, lectures, workshops and social events in a nonresidential, homelike setting.
About American BioScience, Inc.
American BioScience, Inc. is a privately held biotechnology company focused on the discovery, development and delivery of next-generation therapeutics including biologically active molecules already existing within the human biological system, for the treatment of life-threatening diseases. ABI owns a majority interest in American Pharmaceutical Partners, Inc.
About American Pharmaceutical Partners, Inc.
American Pharmaceutical Partners, Inc. is a specialty drug company that develops, manufactures and markets injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. Abraxis Oncology, the proprietary division of APP, is devoted entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). For more information, visit APP’s website at www.appdrugs.com and www.abraxisoncology.com.
Contacts: PondelWilkinson Inc.
Rob Whetstone/Wade Huckabee (310) 279-5980
American BioScience, Inc.
CONTACT: Rob Whetstone or Wade Huckabee, both of PondelWilkinson Inc.,+1-310-279-5980, for American BioScience, Inc.
